RT Journal Article
SR Electronic
T1 Changing pattern in presentation of infective conjunctivitis during COVID-19 pandemic in a tertiary eye hospital in Nepal
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.01.24314750
DO 10.1101/2024.10.01.24314750
A1 Thinley
A1 Gurung, Reeta
A1 Gurung, Hom Bahadur
A1 Poudel, Manish
A1 Banjara, Pradeep
YR 2024
UL http://medrxiv.org/content/early/2024/10/02/2024.10.01.24314750.abstract
AB Purpose To evaluate changes in the pattern of presentation of infective conjunctivitis during COVID-19 pandemic at a Tertiary Eye Hospital in Nepal.Methods This was a single-center retrospective cross-sectional study that analyzed cases of infective conjunctivitis at Tilganga Institute of Ophthalmology, Nepal from January 2018 to December 2022 using data from electronic medical records. The data from 2020 and 2021 were considered as the COVID era. Cases of corneal foreign body during the same period were used as a control.Results The number of cases of infective conjunctivitis decreased by 64.86% (95% CI, -64.82% to -64.94%; p<0.001) during the COVID-19 pandemic. Sharp decrease was noted after the implementation of lockdowns and preventive measures. However, in post-pandemic era, the number of cases increased by 24.6 % (95% CI, +24.57% to +24.66%; P<0.001). In contrast, the cases of corneal foreign body increased by 41.63 % (95% CI, +41.59% to +41.66%; p <0.001).Conclusion The number of cases of infective conjunctivitis at our hospital decreased significantly during the COVID-19 pandemic. This reduction in number and change in pattern of presentation might be attributed to the widespread implementation of preventive public health measures during the pandemic period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Committee of Tilganga Institute of Ophthalmology with approval no. Ref:20/2022 dated 13/11/2022.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.